NAT-GEFITINIB 250 MG
GEFITINIB : 250 MG · DIN 02491796 · NATCO PHARMA (CANADA) INC
Health Canada status: DORMANT
What is NAT-GEFITINIB?
NAT-GEFITINIB 250 MG contains GEFITINIB : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02491796, held by NATCO PHARMA (CANADA) INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 01-Mar-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02491796 |
|---|---|
| Brand name | NAT-GEFITINIB |
| Generic / active ingredient | GEFITINIB : 250 MG |
| Manufacturer | NATCO PHARMA (CANADA) INC |
| Strength | 250 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01EB01 GEFITINIB |
| AHFS class | 38:00.00 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 01-Mar-2026 |
What can be used instead?
Other Canadian products sharing ATC code L01EB01 GEFITINIB. 3 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-GEFITINIB | 250 MG | TABLET | APOTEX INC | MARKETED | DIN 02468050 |
| IRESSA | 250 MG | TABLET | ASTRAZENECA CANADA INC | MARKETED | DIN 02248676 |
| JAMP GEFITINIB | 250 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02500663 |
| AURO-GEFITINIB | 250 MG | TABLET | AURO PHARMA INC | APPROVED | DIN 02533685 |
| EUGIA-GEFITINIB | 250 MG | TABLET | EUGIA PHARMA INC. | APPROVED | DIN 02547546 |
| SANDOZ GEFITINIB | 250 MG | TABLET | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02487748 |
Who else supplies GEFITINIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. GEFITINIB appears in 27 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.